Zydus Lifesciences - Guided for 2-3 High Value Launches in US over FY27/28
The stock price has corrected by ~25% over last 3 months on account of concerns of high product concentration risk, incremental competition in...
175 Views
Zydus Lifesciences: High Base to Keep EPS Muted, Specialty Growth Key. Maintain ADD
Zydus Life has corrected over 25% from its 52-week high in the last 2-3 months, due to (1) competition in gAsacol HD (Teva, launched in Sep ’24)
251 Views
Pharmaceuticals: Lupin/Zydus lost Myrbetriq patent case in district court
Lupin and Zydus received unfavourable opinion in Mirabegron (gMyrbetriq) patent litigation (against Astellas Pharma) from the District court of...
623 Views
Pharmaceuticals: Pharma dodges first round of US tariff risk
The US government under Trump 2.0 has announced reciprocal tariffs across countries, including ~26% tariff on imports from India
172 Views
HSIE Results Daily: Titan, Infoedge, Zydus Lifesciences, Max Financial, Happiest Minds Technologies
Titan: Consolidated jewellery sales (ex-bullion) grew 27.3% YoY to INR159.9bn (in-line) powered by gold prices growth (up 25% YoY). Domestic...
316 Views